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Background and Aims. The secretion of several adipocytokines, such as adiponectin, retinol-binding protein 4 (RBP4), adipocyte
fatty acid binding protein (aFABP), and visfatin, is altered in subjects with abdominal adiposity; these endocrine alterations could
contribute to increased cardiovascular risk. The aim of the study was to assess the relationship among adiponectin, RBP4, aFABP,
and visfatin, and incident cardiovascular disease. Methods and Results. A case-control study, nested within a prospective cohort, on
2945 subjects enrolled for a diabetes screening program was performed. We studied 18 patients with incident fatal or nonfatal IHD
(Ischemic Heart Disease) or CVD(Cerebrovascular Disease), compared with 18 matched control subjects. Circulating adiponectin
levels were signiﬁcantly lower in cases of IHD with respect to controls. Circulating RBP4 levels were signiﬁcantly increased in CVD
and decreased in IHD with respect to controls. Circulating aFABP4 levels were signiﬁcantly increased in CVD, while no diﬀerence
wasassociatedwithIHD.CirculatingvisfatinlevelsweresigniﬁcantlylowerincasesofbothCVDandIHDwithrespecttocontrols,
while no diﬀerence was associated with CVD. Conclusions. The present study conﬁrms that low adiponectin is associated with
increased incidents of IHD, but not CVD, and suggests, for the ﬁrst time, a major eﬀect of visfatin, aFABP, and RBP4 in the
development of cardiovascular disease.
1.Introduction
Overweight and obesity are associated with a diﬀerent se-
cretion rate of several adipocytokines, such as reduced adi-
ponectin [1] and increased retinol-binding protein 4 (RBP4)
[2], adipocyte fatty acid binding protein (aFABP) [3], and
visfatin [4]. aFABP plays an important role in maintaining
glucose and lipid homeostasis. aFABP has been primarily
regarded as an adipocyte- and macrophage-speciﬁc protein,
b u tr e c e n ts t u d i e ss u g g e s tt h a ti tm a yb em o r ew i d e l ye x -
pressed [5]. Such endocrine modiﬁcations could be respon-
sible, at least partly, for the increased cardiovascular risk
associated with excess fat mass [6]. In particular, low adi-
ponectin levels have been reported to be associated with in-
creased incidence of myocardial infarction in men [7], al-
though other groups did not ﬁnd such association in women
[8]. In elderly, RBP4 concentrations were associated with
Metabolic Syndrome (MetS) and its components in both
genders, and prior cerebrovascular disease in men [9].
A recent study was undertaken to determine plasma
RBP4 and adiponectin levels in subjects with cerebral in-
farction and showed that adiponectin and hypertension were
independent factors contributing to cerebral infarction;
moreover, it has been shown that plasma RBP4 levels in
the subjects with cerebral infarction were signiﬁcantly great-
er than those in control subjects [10]. In addition, it was2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Principal characteristics of the sample enrolled are described in the table.
Ischemic heart diseases Cerebrovascular disease
Controls Cases Controls Cases
Number (women %) 9 (22.2%) 9 (22.2%) 9 (22.2%) 9 (22.2%)
Age (years) 62.9 ± 4.26 3 .6 ±4.96 5 .5 ±11.86 5 .0 ±11.7
Waist (cm) 98.8 ± 6.89 8 .6 ±6.79 4 .9 ±9.39 3 .9 ±9.0
BMI (kg/m2)2 8 .0 ± 1.72 8 .2 ±2.52 5 .1 ±2.42 4 .7 ±3.0
Total colesterol (mmol/L) 5.39 ±0.83 6.21 ±0.95 .38 ±0.82 5.8 ±1.55
HDL colesterol (mmol/L) 1.26 ±0.38 1.41 ±0.51 .65 ±0.67 1.45 ±0.43
Triglyceride (mmol/L) 1.19 (1;2.67) 1.8 (1.42;3.42) 1.7 (1.18;2.88) 1.17 (0.96;1.64)
Fasting glycemia (mmol/L) 5.52 ±0.89 5.99 ±1.64 4.98 ±0.85 .77 ±0.91
Diabetes mellitus (%) 22.2 22.2 11.1 11.1
Hypertension∗ (%) 33.3 77.8 66.7 66.7
High fasting glycemia∗ (%) 11.1 22.2 11.1 11.1
High waist∗ (%) 55.6 68.7 66.7 44.4
Low HDL colesterol∗(%) 33.3 22.2 11.1 11.1
Hypertriglyceridaemia∗ (%) 44.4 55.6 22.2 33.3
∗as deﬁned by NCEP criteria.
reported that visfatin is capable of reducing myocardial
injury when administered at the time of myocardial reperfu-
sion in both in situ murine heart and in the isolated murine
cardiomyocytes [11].
The relationships between RBP4, aFABP, and visfatin,
withrespecttoincidentcardiovasculardisease,havenotbeen
assessed, so far, in human models.
2. Patientsand Methods
A case-control study was performed within the cohort en-
rolled in the Firenze-Bagno a Ripoli (FIBAR) study [12].
Brieﬂy, all subjects aged 40–75 years without known diabetes
were invited to participate to a diabetes screening program
through newspaper and TV advertising, public conferences,
and letters from family doctors. The local ethical committee
approved the study, and each participant provided informed
written consent. Venous blood samples for lipid proﬁle and
plasmaglucosewerecollectedinthemorning,afterovernight
fast (>8hrs).Allsubjects(n = 2945) underwent a standard
oral glucose tolerance test (75g in 50% water solution, with
measurement of plasma glucose after 120 minutes). Blood
pressure was measured in sitting position, after a 5-min rest
using a mercury sphygmomanometer with a cuﬀ of appro-
priate size; the mean of three measurements of systolic and
diastolic blood pressure was considered for analysis. Patients
were considered hypertensive if they were taking antihy-
pertensive medication and/or if their oﬃce blood pressure
was ≥140/90mmHg [13]. Laboratory determinations were
performed in the Central Laboratory of Careggi Hospital in
Florence. Plasma glucose was measured by a glucose oxidase
method; total and HDL cholesterol, and triglycerides were
determined by an automated enzymatic method (Beckman,
Brea, USA). Metabolic Syndrome was diagnosed according
to NCEP criteria [14, 15]. The mean followup was 33.6 ±6.7
months. Nonfatal cases requiring hospitalization and fatal
of IHD (Ischemic Heart Disease) and CV (Cerebrovascular
disease) were considered. Nonfatal cases were identiﬁed
through the regional hospital discharge system using Inter-
national Classiﬁcation of Diseases (ICD) codes 410–414,
420–429, 798–799, and 430–434, 436–438 for IHD and CV,
respectively. Fatal IHD and CV were identiﬁed through
queries to the registry oﬃce of the municipalities of Florence
and Bagno a Ripoli, selecting cases with the same ICD codes
listed above. Incident cases of IHD (n = 9 )a n dC V( n = 9)
in individuals without any previous history of cardiovascular
disease were compared with control subjects free of events
fromthesamecohort.Foreachcase,theﬁrstavailablesubject
matched for age (±2y e a r s ) ,g e n d e r ,B M I( ±2Kg/m 2), waist
(±3cm), and degree of glucose tolerance was selected as
control. In cases and control subjects, serum adipocytokynes
were measured using ELISA test for adiponectin (Linco
Research, USA) and human Adipocyte aFABP (BioVendor
GmbH, Germany), and EIA test for Visfatin and RBP4
(PhoenixPharmaceuticals,USA).Statisticalanalysiswasper-
formed with SPSS 12.0.1. Data were expressed as mean ±
SD, when normally distributed, and as median (quartiles),
when their distribution was not normal. For comparisons
between groups, unpaired two-tailed Student’s t-tests and
Mann-Whitney U tests were applied to normally and non-
normally distributed parameters, respectively. Stepwise lo-
gistic regression was used for multivariate analysis.
3. Results
Cardiovascular events were detected in 18 subjects (9 IHD
and 9 CV). The characteristics of cases of IHD and CVD as
well as of respective controls are summarized in Table 1.P a -
tients with IHD showed a signiﬁcantly higher prevalence
of hypertension, in comparison with their controls. No
other signiﬁcant diﬀerences between cases and controls were



































































































































Figure 1: Comparison of mean adipocytokines levels between cases (black bars) of IHD and CVD and their controls (white bars). ∗P < 0.05,
∗∗P < 0.01. (a) Adiponectin is signiﬁcantly reduced only in IHD with respect to controls. (b) RBP4 is reduced in a signiﬁcant manner in
IHD and increased signiﬁcantly in CVD with respect to controls. (c) aFABP is signiﬁcantly increased only in CVD with respect to controls.
(d) Visfatin is signiﬁcantly reduced both in IHD and CVD with respect to controls.
lower in cases of IHD with respect to controls (P =
0.021), while no diﬀerence was associated with CVD cases
Figure 1(a)). The diﬀerence of adiponectin levels between
cases of IHD and their controls retained statistical signif-
icance at multivariate analysis after adjustment for compo-
nents of the metabolic syndrome, with an increased risk of
IHD of 61% (2–161) (P<0.05) for each decrement of
1μg/mL. Circulating RBP4 levels were signiﬁcantly increased
in cases of CVD with respect to controls (P = 0.001),
while they resulted decreased in a signiﬁcant manner in
cases of IHD respect to controls (P = 0.006) (Figure 1(b)).
Circulating aFABP levels were signiﬁcantly increased in cases
of CVD with respect to controls (P = 0.041), while no
diﬀerencewasassociatedwithIHD(Figure 1(c)).Circulating
visfatin levels were signiﬁcantly lower in cases of both CVD
and IHD with respect to controls (P = 0.014 and P = 0.035,
resp.) (Figure 1(d)).
4. Discussion
An u m b e ro fd i ﬀerent hormones produced by fat tissue have
been identiﬁed in the last few years, and some of those mol-
ecules have been found to be associated with the regula-
tion of insulin sensitivity. Since visceral adiposity and insu-
lin resistance are known to be associated with increased car-
diovascular risk [16], it could be speculated that some adipo-
cytokines mediate this relationship.
Our data have revealed diﬀerent results among the dif-
ferent adipocytokines, accordingly to the observation that
in cardiovascular events, predictive factors have a diﬀerent
weight: hypertension is more predictive for CVD, while hy-
percholesterolemia is more predictive for IHD.
Moreover present data conﬁrm that low adiponectin is
an independent predictor of IHD, even after adjustment for
components of the metabolic syndrome; on the other hand,4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
adiponectin levels are not associated with the incidence of
CVD. This conﬁrms previous results [17, 18], highlighting
pathophysiological diﬀerences between coronary and cere-
brovascular disease.
RBP4 is secreted by adipose tissues and hepatocytes [19],
and there are controversial reports regarding the eﬀect of
RBP4 on insulin resistance. It has been described that plas-
ma RBP4 is increased in subjects with obesity, impaired
glucose tolerance, and diabetes mellitus [20–24], but other
studies did not support the relation between RBP4 and
insulin resistance [25–30]. Recently, Sasaki et al. have shown
increased levels of RBP4 in a sample of 58 Japanese with
cerebral infarction which appeared to be signiﬁcantly higher
than in age- and sex-matched control subjects. Since present
studyisacase-controlstudywithstrongcriteria ofmatching,
the statistical relevance of such a small sample of patients is
ampliﬁed by the method of the clinical analysis. Our data
conﬁrm this correlation between the RBP4 and CVD and for
the ﬁrst time demonstrate a correlation with IHD.
Moreover, our study, for the ﬁrst time, demonstrates that
visfatin and aFABP have major eﬀect on the development of
cardiovascular disease, in particular, visfatin levels are sig-
niﬁcantly decreased both in cases of CVD and IHD, while
increased aFABP levels are correlated with CVD but not with
cases of IHD. On the basis of our observation, the measure-
ment of adiponectin, RBP4, aFABP, and visfatin could be
considered along with other cardiovascular risk factors in a
larger clinical setting, for predicting the risk of developing
major cardiovascular events.
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